Oraya Therapeutics

It All Starts with Oraya:

Introducing a New Option for Wet AMD

Radiotherapy has come of age. While long used for the treatment of cancer, recent improvements introduced by Oraya have brought radiation to the forefront of AMD therapy. CNV appears to be a multi-component disease involving neovascular growth, vascular leakage, matrix deposition, remodeling, and inflammation. Radiation has the ability to inhibit rapidly proliferating vascular tissue and diminish new blood vessel growth. It can also reduce inflammation and minimize scar formation. Intended as a one-time treatment, Oraya Therapy is non-invasive, quick and easily tolerated.

With Oraya Therapy, we’re raising the bar and lowering the burden.

The Oraya Therapy provides the following advantages:

Innovative Technology

Oraya Therapy raises the bar in the treatment of wet AMD by using state-of-the- art technology that advances radiotherapy to new levels of control and precision targeting. The Oraya system uses advanced X-ray tube positioning to ensure precise targeting and control. The patient’s eye is secured by the proprietary I-Guide™ Eye Stabilization Device that immobilizes the globe to assure accurate treatment. This stereotactic approach results in precise delivery of therapy to the macula while protecting surrounding tissue from radiation exposure.

Ease of Use and Patient Comfort

Delivered non-invasively in an outpatient setting, Oraya Therapy is designed to ease the burden of wet AMD treatment for both the patient and the physician by reducing the number of anti-VEGF injections. The procedure requires only a topical anesthetic, and patients are able to leave within 15 to 20 minutes. The actual treatment time is approximately four minutes.

Read about our clinical trials.

Learn more about Oraya Therapy and the principles and safely of radiation treatment for wet AMD.

Back To Top

 

EURETINA 2013, Hamburg: Oraya Seminar Presentations
Oraya Therapy Video Select For Success – Screening patients and treating with the Oraya Therapy A. Luff (UK)

Oraya Therapy Video Lower the Burden – 2 year efficacy of stereotactic radiotherapy for the treatment of wet AMD D. Moshfeghi (USA)

Oraya Therapy Video Not What you Expect – Identify and assess microvascular abnormalities following Oraya Therapy U. Charkravarthy (Nothern Ireland)


2012 EURETINA Seminar Videos
The INTREPID Trial of Stereotactic Radiosurgery for Choroidal Neovascularization
in AMD
- Peter K. Kaiser, M.D.
The INTREPID TRIAL DESIGN
— Moshfeghi D. More >
The INTREPID TRIAL of Stereotactic Radiosurgery for Choroidal Neovascularization in AMD
— Kaiser P, et al.  More >
2-year subpopulation results of the INTREPID Trial of Stereotactic Radiosurgery for Choroidal Neovascularization in AMD
— Němec P, et al. More >
© 2014 All rights reserved to Oraya Therapeutics The IRay® Radiotherapy System is an investigational device and is not available for sale in the U.S.A. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.